FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution

FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution
  • Organogenesis Holdings Inc ORGO has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio. 
  • Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal. 
  • Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance.
  • Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds. 
  • PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.
  • Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.

Posted In: BriefsNewsPenny StocksHealth CareSmall CapFDAGeneral